Exploration into the neuroimmune mechanisms of AUD has revealed new molecular targets and potential drug candidates for advancing treatment strategies. Now researchers must delve deeper into the genetic components of cell-type signaling pathways in different brain regions, in a unified effort to define targetable neuroimmune molecules and biomarkers in animal drinking models with potential efficacy in the human laboratory. Integrated approaches across disciplines will be critical to gain the understanding necessary to advance work in animal models to the clinical level.
